Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745076 · ClinicalTrials.gov registry record · Phase 2
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
A Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 5
- Study locations
NCT06745076 is a Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 125 participants, below the 239-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (48% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06745076, a Phase 2 study of Classic Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as nivolumab, doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many types of tumors tend to lose cells or release different types of cellular products including their DNA, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids and, based on the result, assign patients to a reduced number of chemotherapy treatments or the standard number of chemotherapy treatments. Using ctDNA to assign a personalized reduction of chemotherapy may be effective in treating patients with advanced Hodgkin lymphoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Doxorubicin
- PROCEDURE Echocardiography Test
- DRUG Dacarbazine
Study Locations (5)
California
- City of Hope - Irvine
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2033-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06745076
The ClinicalTrials.gov registry entry for NCT06745076 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (48% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06745076 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT06745076 about?
NCT06745076 is a clinical study titled "Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma". This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to ne...
What is the current status of trial NCT06745076?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-03-06. Estimated completion is 2033-01-03.
What conditions does trial NCT06745076 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Advanced Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8.
What interventions are being tested in trial NCT06745076?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Doxorubicin (DRUG), Echocardiography Test (PROCEDURE), Dacarbazine (DRUG).
Who is sponsoring clinical trial NCT06745076?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745076 being conducted?
This trial has 5 study locations across California, Massachusetts, Missouri, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.